Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
11,64 USD | +0,87% | +2,92% | +43,17% |
Omzet 2024 * | 161 mln. 151 mln. | Omzet 2025 * | 413 mln. 386 mln. | Marktkapitalisatie | 3,25 mld. 3,04 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -352 mln. -329 mln. | Nettowinst (verlies) 2025 * | -245 mln. -229 mln. | EV/omzet 2024 * | 19,3 x |
Nettoliquiditeiten 2024 * | 133 mln. 125 mln. | Nettoliquiditeiten 2025 * | 251 mln. 234 mln. | EV/omzet 2025 * | 7,27 x |
K/w-verhouding 2024 * |
-8,97
x | K/w-verhouding 2025 * |
-16,1
x | Werknemers | 557 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,7% |
Recentste transcriptie over Iovance Biotherapeutics, Inc.
1 dag | -1,03% | ||
1 week | +2,92% | ||
Lopende maand | -21,46% | ||
1 maand | -17,15% | ||
3 maanden | +53,36% | ||
6 maanden | +214,59% | ||
Lopend jaar | +43,17% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30-09-16 |
Director of Finance/CFO | 51 | 14-12-20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20-07-11 |
Director/Board Member | 56 | 07-06-16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15-03-18 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.95% | 11 M€ | -6,03% | - | |
0.93% | 1 M€ | 0,00% | - | |
0.14% | 0 M€ | 0,00% | - | |
0.11% | 2 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 11,64 | +0,87% | 2 489 561 |
25-04-24 | 11,54 | -1,45% | 3 398 958 |
24-04-24 | 11,71 | -1,26% | 2 932 120 |
23-04-24 | 11,86 | +4,77% | 3 895 064 |
22-04-24 | 11,32 | +0,09% | 2 404 929 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,17% | 3,25 mld. | |
-20,45% | 10,82 mld. | |
-35,86% | 2,11 mld. | |
-17,21% | 2,08 mld. | |
-29,81% | 1,48 mld. | |
+17,56% | 1,02 mld. | |
-4,37% | 733 mln. | |
-37,00% | 391 mln. | |
-46,94% | 377 mln. | |
+13,32% | 332 mln. |